Skip to main content
. 2022 Sep 13;21:299–312. doi: 10.1016/j.bioactmat.2022.08.028

Fig. 5.

Fig. 5

CD8+ T cell infiltration into the tumor tissue after treatment with EPI, EZ, GHZ, EHGZ, mEHGZ, anti-PD-L1 antibody, and mEHGZ + anti-PD-L1 antibody at an EPI dose of 3 mg/kg or an antibody dose of 100 μg for three time every two days to activate the immune microenvironment. A) Schematic illustration of the released antigens and DAMPs triggered by ICD to reverse an immunosuppressive microenvironment to an immunosupportive one. B–C) The proportion of CD8+ T cells in the tumor tissue after different treatments. D-E) Quantification of CD8+ T cells in the spleen and lymph nodes via flow cytometry. F) Immunofluorescence slices indicating CD8+ T cells infiltration into the tumor tissue. (blue: nuclei; red: CD4+ T cells; green: CD8+ T cells; scale bar = 100 μm). G) Flow cytometric analysis of IFN-γ CD8+ T cells in the tumor tissue. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.